Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the recipient of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 447,400 shares, anincreaseof314.3% from the June 30th total of 108,000 shares. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is presently 0.3 days. Approximately1.4% of the shares of the stock are short sold. Approximately1.4% of the shares of the stock are short sold. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is presently 0.3 days.

Analysts Set New Price Targets

• Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Several research analysts have commented on the stock. JMP Securities reissued a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Guggenheim set a $8.00 price objective on shares of Vigil Neuroscience and gave the company a "neutral" rating in a research report on Thursday, May 22nd. HC Wainwright cut shares of Vigil Neuroscience from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $14.00 to $8.00 in a research report on Tuesday, May 27th. William Blair cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Wedbush cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and lowered their price objective for the company from $13.00 to $8.00 in a research report on Thursday, May 22nd. Ten investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $10.80.

Read Our Latest Report on VIGL

Hedge Funds Weigh In On Vigil Neuroscience

Large investors have recently added to or reduced their stakes in the business. BVF Inc. IL increased its position in shares of Vigil Neuroscience by 121.3% in the first quarter. BVF Inc. IL now owns 4,013,633 shares of the company's stock valued at $7,144,000 after acquiring an additional 2,200,000 shares during the period. Aberdeen Group plc increased its position in shares of Vigil Neuroscience by 226.3% in the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company's stock valued at $3,070,000 after acquiring an additional 1,196,048 shares during the period. Blair William & Co. IL increased its position in shares of Vigil Neuroscience by 219.1% in the first quarter. Blair William & Co. IL now owns 1,033,577 shares of the company's stock valued at $1,840,000 after acquiring an additional 709,677 shares during the period. Woodline Partners LP increased its position in shares of Vigil Neuroscience by 239.1% in the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company's stock valued at $831,000 after acquiring an additional 344,614 shares during the period. Finally, 683 Capital Management LLC increased its position in shares of Vigil Neuroscience by 24.3% in the first quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company's stock valued at $3,097,000 after acquiring an additional 340,000 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Price Performance

Shares of NASDAQ:VIGL opened at $8.05 on Friday. The stock has a market cap of $383.90 million, a PE ratio of -3.93 and a beta of 3.33. The company's fifty day moving average is $7.97 and its 200 day moving average is $4.27. Vigil Neuroscience has a 52 week low of $1.31 and a 52 week high of $8.10.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. Sell-side analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current year.

About Vigil Neuroscience

(Get Free Report)

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

Recommended Stories

• Five stocks we like better than Vigil Neuroscience
• The How And Why of Investing in Oil Stocks
• Bitcoin and Dividends: A Winning Combo in These 3 ETFs
• Consumer Discretionary Stocks Explained
• Is PG&E an AI Power Play? Why Options Traders Are Betting Big
• What is Insider Trading? What You Can Learn from Insider Trading
• MarketBeat Week in Review – 07/28 - 08/01

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vigil Neuroscience Right Now?

Before you consider Vigil Neuroscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vigil Neuroscience wasn't on the list.

While Vigil Neuroscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here